AJP - Renal Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol (January 7, 2009). doi:10.1152/ajprenal.90705.2008
This Article
Right arrow Full Text (PDF)
Right arrow Corrigendum
Right arrow All Versions of this Article:
296/3/F575    most recent
90705.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Park, F.
Right arrow Articles by Avner, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, F.
Right arrow Articles by Avner, E. D.
Submitted on November 24, 2008
Revised on December 22, 2008
Accepted on January 5, 2009

Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD

Frank Park1*, William E Sweeney Jr.1, Guanggfu Jia1, Talha Akbulut1, Benjamin Mueller1, John R. Falck2, Saritha Birudaraju2, Richard J. Roman1, and Ellis D. Avner

1 Medical College of Wisconsin
2 UT Southwestern Medical Center @ Dallas

* To whom correspondence should be addressed. E-mail: fpark{at}mcw.edu.

20-hydroxyeicosatetraenoic acid (20-HETE) has been implicated as a potential mediator in epithelial cell proliferation and cyst formation in polycystic kidney disease (PKD). In the present study, we studied the effects of chronic blockade of 20-HETE synthesis in an orthologous rodent model of autosomal recessive polycystic kidney disease (ARPKD), the PCK rat. Reverse transcription-polymerase chain reaction (RT-PCR) analysis indicated that the expression of CYP4A1, CYP4A2, CYP4A3, and CYP4A8 mRNA was increased 2- to 4- fold in cystic PCK compared to non-cystic SD rat kidneys. Daily administration of a 20-HETE synthesis inhibitor, HET-0016 (10 mg/kg/day i.p.) for 4-7 weeks significantly reduced kidney size by 24% from 4.95 ± 0.19 g in vehicle-treated PCK rats to 3.76 ± 0.15 g (n=4). Collecting tubule morphometric cystic indices were reduced in HET-0016 treated PCK rats (2.1 ± 0.2; n=4) compared to vehicle-treated PCK rats (4.4 ± 0.1; n=4). The cellular mechanism by which 20-HETE may play a role in cyst formation has not been well characterized, but there was a significantly lower (P<0.05) level of intracellular cAMP and decreased phosphorylation (activation) of Erk1/2 protein in PCK rat kidneys (n=3) treated with HET-0016 . These studies indicate a potential role of 20-HETE in cyst formation in the orthologous rodent PCK model of ARPKD.




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
T. Akbulut, K. R. Regner, R. J. Roman, E. D. Avner, J. R. Falck, and F. Park
20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR- and c-Src-dependent mechanism
Am J Physiol Renal Physiol, September 1, 2009; 297(3): F662 - F670.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.